文献速递心境障碍

重度抑郁症与炎症性皮肤病共享全身免疫特征及潜在治疗靶点

Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases.
PubMed 文献 · Mol Psychiatry · 2026-02-11

该研究比较了重度抑郁症(MDD)患者与特应性皮炎(AD)、银屑病及健康对照的血浆蛋白质组,发现MDD与AD共享Th2偏移等免疫特征。计算机药物重定位分析识别出靶向IL-4Rα的度普利尤单抗可显著逆转MDD相关蛋白质失调,并在慢性社会挫败应激小鼠模型中验证了IL-4Rα药理学抑制可预防应激诱导的社会回避行为。

要点

  • MDD患者血浆蛋白质组显示Th2偏移及免疫/神经血管相关蛋白失调,与AD共享特征。
  • 计算分析提示度普利尤单抗(靶向IL-4Rα)可逆转MDD中Th2相关炎症蛋白失调。
  • 小鼠CSDS模型中IL-4Rα药理学抑制预防了应激诱导的社会回避行为。

核心结论

  • Th2轴在MDD中可能具有重要作用,靶向Th2有望成为疾病修饰治疗。

研究设计与样本

  • 研究比较MDD患者与AD、银屑病及健康对照的血浆蛋白质组,并进行计算机药物重定位分析及小鼠CSDS模型实验。

主要发现

  • MDD患者蛋白质组特征与AD共享Th2偏移及其他免疫/神经血管相关蛋白失调。
  • 度普利尤单抗(靶向IL-4Rα,抑制Th2轴)在计算分析中显著影响MDD特征,逆转多种Th2信号相关炎症蛋白失调。
  • 小鼠CSDS模型中IL-4Rα药理学抑制预防了应激诱导的社会回避行为。

关键数值与推荐

  • 计算机药物重定位分析识别度普利尤单抗可显著影响MDD蛋白质组特征。
  • 小鼠CSDS模型中IL-4Rα抑制预防应激诱导的社会回避行为。

临床怎么用

  • 提示精神科可关注MDD患者的Th2相关免疫特征,并探索靶向IL-4Rα等免疫调节药物的转化研究。

局限性

  • 原文未报告临床抗炎药物试验的疗效数据,药物重定位结果为计算预测,需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) is a prevalent neuropsychiatric disorder associated with significant morbidity and mortality. Increasing evidence suggests that a subset of MDD patients exhibit a dysregulated immune system. However, few clinical studies have tested the efficacy of anti-inflammatory drugs in reducing symptoms of depression. In contrast, targeted immunomodulatory drugs have revolutionized the treatment of inflammatory skin disorders, such as atopic dermatitis (AD) and psoriasis. To assess the viability of a targeted treatment approach in MDD, we first compared the blood proteomic profiles of patients with MDD to those of patients with AD, psoriasis, and healthy controls (HCs). We demonstrated that the proteomic signatures of MDD patients share Th2 skewing and dysregulation of other immune/neurovascular-related proteins with AD. Next, we performed an in-silico drug repurposing analysis to test whether common biologics used in dermatology could also affect the dysregulated proteomic signature observed in MDD patients. This computational approach identified dupilumab, which targets the IL-4 receptor α subunit (IL-4Rα) and thus inhibits the Th2 axis, as significantly affecting the MDD signature by reversing the dysregulation of several inflammatory proteins related to Th2 signaling. Finally, in a mouse model of chronic social defeat stress (CSDS), we showed that pharmacological inhibition of IL-4Rα prevented stress-induced social avoidance behavior. Our findings underscore the potential role of the Th2 axis in MDD, highlighting the potential of specifically targeting Th2 as a disease-modifying treatment. Additionally, the back-translational drug repurposing strategy employed in this study may offer a novel approach to identify immunomodulatory drugs in psychiatry.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. He H, Cathomas F, Parise LF, et al. Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases. Mol Psychiatry. 2026. PMID: 41673463. doi:10.1038/s41380-025-03383-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。